HC Wainwright Has Negative Outlook of Evolus FY2026 Earnings

Evolus, Inc. (NASDAQ:EOLS) – Stock analysts at HC Wainwright dropped their FY2026 EPS estimates for shares of Evolus in a note issued to investors on Tuesday, February 3rd. HC Wainwright analyst D. Tsao now expects that the company will post earnings of ($0.29) per share for the year, down from their previous estimate of $0.05. HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Evolus’ current full-year earnings is ($0.61) per share. HC Wainwright also issued estimates for Evolus’ FY2027 earnings at $0.10 EPS, FY2028 earnings at $0.55 EPS, FY2029 earnings at $0.95 EPS and FY2030 earnings at $1.31 EPS.

Evolus (NASDAQ:EOLS) last announced its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.05. The company had revenue of $68.97 million during the quarter, compared to analyst estimates of $91.23 million.

EOLS has been the subject of a number of other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a report on Monday, December 22nd. BTIG Research reduced their target price on shares of Evolus from $18.00 to $13.00 and set a “buy” rating on the stock in a research report on Thursday, January 22nd. Wall Street Zen raised shares of Evolus from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Mizuho set a $15.00 price target on shares of Evolus in a research note on Wednesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $17.50.

Evolus Price Performance

Shares of NASDAQ EOLS opened at $4.50 on Thursday. Evolus has a 1-year low of $4.41 and a 1-year high of $17.12. The company has a market capitalization of $291.69 million, a price-to-earnings ratio of -4.89 and a beta of 1.11. The business has a 50-day moving average of $6.01 and a 200-day moving average of $6.70.

Insiders Place Their Bets

In other news, insider David Moatazedi sold 10,539 shares of the business’s stock in a transaction dated Monday, December 22nd. The shares were sold at an average price of $7.15, for a total value of $75,353.85. Following the completion of the sale, the insider owned 354,388 shares of the company’s stock, valued at approximately $2,533,874.20. The trade was a 2.89% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 5.90% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Evolus

A number of hedge funds have recently bought and sold shares of the company. Rhumbline Advisers raised its stake in Evolus by 2.0% during the second quarter. Rhumbline Advisers now owns 85,093 shares of the company’s stock valued at $784,000 after buying an additional 1,657 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Evolus by 5.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 33,289 shares of the company’s stock worth $400,000 after acquiring an additional 1,838 shares in the last quarter. Invesco Ltd. increased its holdings in shares of Evolus by 7.5% in the 2nd quarter. Invesco Ltd. now owns 34,283 shares of the company’s stock valued at $316,000 after acquiring an additional 2,383 shares during the last quarter. Larson Financial Group LLC raised its position in shares of Evolus by 136.6% during the 4th quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after acquiring an additional 2,837 shares in the last quarter. Finally, Manchester Capital Management LLC bought a new position in Evolus during the second quarter worth $26,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.